Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 5/20 | 0.41 |
| ▸ | EGFR | P00533 | 4/20 | 0.41 |
| ▸ | KDR | P35968 | 4/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111262 | 0.92 | ALDH1A1 (0.42) | PDGFRBEGFRKDRABCG2PDGFRA | |
| SCHEMBL3113207 | 0.84 | KDR (0.61) | PDGFRBEGFRKDRABCG2PDGFRA | |
| SCHEMBL13609660 | 0.81 | PDGFRB (0.41) | PDGFRBEGFRKDRPDGFRAHDAC8 | |
| SCHEMBL2259057 | 0.76 | HTT (0.37) | ABCG2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL2259061 | 0.75 | MEN1 (0.37) | ABCG2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL3109889 | 0.75 | KDR (0.61) | PDGFRBEGFRKDRABCG2PDGFRA | |
| SCHEMBL2263021 | 0.73 | EGFR (0.55) | PDGFRBEGFRKDRABCG2PDGFRA | |
| SCHEMBL14410306 | 0.73 | KDR (0.61) | PDGFRBEGFRKDRPDGFRAHDAC8 | |
| SCHEMBL2256621 | 0.71 | ABCG2 (0.51) | PDGFRBEGFRKDRABCG2ABCC1 | |
| SCHEMBL3108708 | 0.71 | ABCG2 (0.73) | PDGFRBEGFRKDRABCG2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989462-B2 | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989462-B2 | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080004297-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080004297-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| EP-1833482-A2 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006074147-A2 | NITROGEN CONTAINING BICYCLIC COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004297-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | PDGFRB 2620/4885EGFR 2915/4885KDR 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.